A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent NSCLC

Study Name:
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Targeted Disease(s):
Lung Cancer

Purpose of Study:

The purpose of this study is to assess the safety profile of nivolumab plus relatlimab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves progression free survival (PFS) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell LUNG CANCER (NSCLC).

Study Dates:
November 30, 2020 - July 1, 2026

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Bristol Myers Squibb

ClinicalTrails.gov Identifier:
NCT04623775

Register for Trial

No upcoming events near you